Stockwinners Market Radar for December 21, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST iCoreConnect Inc trading halted, news pending

18:36 EST Four Corners Property Trust acquires nine American Family Care properties - Four Corners Property Trust announces the acquisition of nine American Family Care properties for $21.2M. American Family Care is an urgent care, family care, and primary care operator with 384 clinics across 33 states, known for its patient-first approach to providing high-quality healthcare services. The properties are located in strong retail corridors in Alabama (7) and Tennessee (2) and are corporate-operated under long term, triple net leases with approximately 14 years of term remaining.

17:57 EST Braze general counsel Wiseman sells 41,210 class A shares - In a regulatory filing, Braze general counsel Susan Wiseman disclosed the sale of 41,210 class A common shares of the company on December 18 at a price of $45.09 per share.

17:41 EST Qualcomm comments on trial verdict that it did not breach Arm license - The company said, "We are pleased with today's decision. The jury has vindicated Qualcomm's (QCOM) right to innovate and affirmed that all the Qualcomm products at issue in the case are protected by Qualcomm's contract with Arm (ARM). We will continue to develop performance-leading, world class products that benefit consumers worldwide, with our incredible Oryon ARM-compliant custom CPUs."

17:29 EST Centessa CEO Saha sells 55,000 ordinary shares - In a regulatory filing, Centessa Pharmaceuticals CEO Saurabh Saha disclosed the sale of 55,000 ordinary shares of the company on December 20 at a price of $17.4374 per share.

17:25 EST Rolls-Royce awarded $1.43B Air Force contract modification - Rolls-Royce has been awarded a $1.43B contract modification to a previously awarded contract for the T108 propulsion system sustainment. The modification brings the total cumulative face value of the contract to $3.96B. Work will be performed at Robbins Air Force Base, Georgia; and other locations in the contiguous and outside the contiguous U.S., and is expected to be completed by Nov. 30, 2032. FY25 operation and maintenance funds in the amount of $74.64M will be obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:21 EST General Dynamics awarded $235.48M Navy contract modification - General Dynamics was awarded a $235.48M cost-plus-fixed-fee modification for engineering, technical, design agent, and planning yard support for operational strategic and attack submarines. Work is expected to be completed by September 2025. FY24 other procurement funds in the amount of $9.36M, FY25 other procurement funds in the amount of $6.38M; FY24 research, development, test and evaluation funds in the amount of $2.39M and FY25 operations and maintenance funds in the amount of $989,000, will be obligated at time of award, of which $3.38M will expire at the end of the current fiscal year. Naval Sea Systems Command is the contracting activity.

17:05 EST Stran & Company receives delisting determination from Nasdaq - Stran & Company announced that it received a letter from Nasdaq, issuing a staff delisting determination. The staff determination noted that the staff had notified the company on June 21, August 23 and November 21 that the company did not comply with Nasdaq Listing Rule 5250 because the company had not filed its quarterly reports on Form 10-Q for the periods ended March 31, June 30 and September 30 with the SEC. The staff determination noted that, based on the staff's review and the materials submitted on August 20, the staff granted the company an exception until December 16 to regain compliance with the filing rule. The staff determination stated that the company had not met the terms of the exception. Specifically, the company has not filed the Forms 10-Q as required by the filing rule. The staff determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the company's common stock.

17:01 EST Jiayin Group announces purchase of commercial property - Jiayin Group announced that it entered into a definitive agreement on December 17, 2024 to purchase certain commercial property located in Shanghai, China of approximately 43,500 square meters for total cash consideration of approximately RMB1.35B. The completion of the purchase is subject to customary closing conditions. The Commercial Property will primarily be used as the company's new headquarters to meet the demand arising from the continuing growth of the company's businesses.

16:56 EST Rumble announces $775M strategic investment from Tether - Rumble "announced that it has entered into a definitive agreement for a strategic investment of $775 million from Tether, the largest company in the digital assets industry and the most widely used dollar stablecoin across the world with more than 350 million users. The Company will use $250 million of the proceeds to support growth initiatives and the remaining proceeds to fund a self tender offer for up to 70 million of its Class A Common Stock, at the same price ($7.50 per share) as Tether's investment. Following the completion of the transaction, Chris Pavlovski, Rumble's Chairman and CEO, will retain his controlling stake in the Company."

16:33 EST Eli Lilly announces FDA approval for Zepbound - Eli Lilly announced the FDA approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea, or OSA, and obesity.

16:32 EST Lexicon receives CRL for Zynquista - Lexicon Pharmaceuticals announced it has received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for Zynquista as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease. This expected communication from the FDA aligns with the company's previously disclosed strategic decision to discontinue launch preparations for Zynquista and focus solely on its clinical development pipeline. "We are sincerely grateful to the patients and physicians who participated in our Zynquista clinical trials, and the broader diabetes community who strongly advocated for Zynquista's approval," said Mike Exton, Ph.D., chief executive officer and director of Lexicon. "Although this was not our desired outcome for sotagliflozin in this indication, we remain steadfast in our commitment to advancing our clinical pipeline, including our near-term focus on LX9211 for diabetic neuropathic pain (DPNP) with top line data from our PROGRESS Phase 2b study anticipated in Q1 2025, and pursuing innovations that we believe can profoundly benefit patients."

16:21 EST Mosaic raises quarterly dividend to 22c from 21c per share - Mosaic declared a quarterly dividend of 22c per share on the company's common stock. The dividend will be paid on March 20, 2025, to stockholders of record at the close of business on March 6, 2025. The dividend is 1c above the prior quarter's dividend.

16:15 EST DocGo approves extension of expiration date of share repurchase program - According to a regulatory filing, on December 20, 2024, the board of directors of DocGo approved an extension of the expiration date of the company's current share repurchase program from December 31, 2024 to June 30, 2025. As previously disclosed, pursuant to the Repurchase Program, the company may purchase up to $26M in shares of the company's common stock. Other than the extension of the program's expiration date, no changes were made to the Repurchase Program. Under the terms of the Repurchase Program, as extended, the company may continue to purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an "open window" and when the company does not possess material non-public information.

16:09 EST Horizon Aircraft announces $8.4M investment - Horizon Aircraft announced it has received an investment from a strategic investor and aerospace supporter, for aggregate proceeds of $8.4M. The strategic financing will fortify Horizon Aircraft's balance sheet, provide stability in the operations, governance and regulatory priorities, and fund further development and flight testing of its hybrid eVTOL, the Cavorite X7. Under the terms of the investment, the investor will receive an aggregate $2.1M in Horizon Class A ordinary shares totaling 4,166,667 shares offered at C$0.50 per share to be issued from treasury. Additionally, the Investor will exchange $6.3M for 4,500 preferred shares to be issued from treasury, each will be convertible to Common Shares at a price of C$0.63 per share for a period of five years. The preferred shares shall have a priority liquidation preference over the common shares. The company shall register the common shares with the United States Securities and Exchange Commission as soon as practically possible, but no later than 90 calendar days from filing.

16:07 EST Expion360 CFO Aydelott resigns - Expion360 announced the resignation of Greg Aydelott, Chief Financial Officer of the company, effective December 31, 2024, due to family health concerns. Aydelott intends to remain available to the company on an ongoing basis as a consultant to ensure a smooth transition. The company's Board of Directors has appointed the company's Chief Executive Officer, Brian Schaffner, as interim Chief Financial Officer, and Principal Financial and Accounting Officer, effective December 31, 2024, and is conducting a search process to identify a new CFO. Schaffner previously served as the CFO of Expion360 from March 2021 through January 2023. "On behalf of our Board of Directors, leadership team and employees, I would like to thank Greg for his outstanding service and commitment over the past three years," said Mr. Schaffner. "He has made significant contributions to Expion360's success, including managing our growth, strengthening our balance sheet, enhancing our planning and budgeting process, and overseeing investments in new technologies and batteries."

16:00 EST authID Inc trading resumes

15:50 EST authID Inc trading halted, volatility trading pause

15:46 EST LiveOne regains compliance with Nasdaq listing requirements - LiveOne announced that the company received a formal written notice from The Nasdaq Stock Market LLC that LiveOne has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and that this matter is now closed. LiveOne's shares of common stock will continue to trade on Nasdaq under the symbol "LVO". This confirmation follows the company's continued efforts to improve its balance sheet by enhancing shareholder value.

15:39 EST Vertex announces FDA exands approval for Trikafta - Vertex Pharmaceuticals announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation that is responsive to Trikafta based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508del CFTR mutations have been added to the Trikafta label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time, the company stated. "Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis. With this approval, even more patients may be able to benefit from a medicine that treats the underlying cause of their disease, and we look forward to continuing the work to extend the approvals and availability of our medicines to patients around the world," added Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.

15:18 EST Exelon reports ICC approves ComEd's refiled multi-year grid plan - The Illinois Commerce Commission yesterday approved, with modifications, ComEd's refiled grid plan presented in March of 2024 after changes to the original plan were requested by the ICC in December of 2023, the company announced. "It prioritizes improvements in system reliability to support the growth of renewable energy and continued economic development, as well as other goals of the Illinois Climate and Equitable Jobs Act, which puts Illinois on a path to a fully decarbonized energy sector by 2045," the company stated. ComEd is a unit of Exelon Corporation.

14:48 EST Swiftmerge Acquisition Corp trading resumes

14:38 EST Swiftmerge Acquisition Corp trading halted, volatility trading pause

14:15 EST Appeals court sides with Amneal over Teva in inhaler patent fight - In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva Pharmaceuticals' (TEVA) ProAir HFA inhaler from the Food and Drug Administration's Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva's patents were incorrectly included on the FDA list. The order posted to the site of the court states: "Teva appealed, and we stayed the district court's order pending our resolution of this case. We now lift the stay and affirm the district court's delisting order." Reference Link

14:02 EST FTC finalizes order with Marriott, subsidiary to address security failures - The Federal Trade Commission announced it has finalized an order requiring Marriott International, and its subsidiary Starwood Hotels & Resorts Worldwide, to implement a comprehensive information security program to settle charges that the companies failed to implement reasonable data security, which led to three large data breaches affecting more than 344 million customers worldwide. "In a complaint first announced in October, the FTC charged that Marriott and Starwood deceived consumers by claiming to have reasonable and appropriate data security, when they in fact failed to deploy reasonable security to protect consumers' personal information. These security failures resulted in at least three separate data breaches that enabled malicious actors to obtain vast amounts of personal information from hundreds of millions of consumers, including passport information, payment card numbers, and loyalty numbers, according to the complaint," the FTC stated.

13:43 EST Washington Trust sees after-tax loss of $70M from asset sales - Washington Trust Bancorp announced balance sheet repositioning transactions "to support continued organic growth and capital generation." The bank sold approximately $409M of available for sale debt securities with a weighted average yield of 2.65% and has agreed to sell approximately $345M in residential mortgage loans with a weighted average rate of 3.03%. The sale of the residential mortgage loans is expected to settle in Q1 of 2025. The sale transactions are expected to result in a net after-tax loss of approximately $70M that will be recognized in Q4. This will cause the company to report a net loss for Q4 and the full year of 2024, but has been entirely funded by the $70M in capital raised through the previously disclosed equity offering. The company said, "Like many banks, we have been carrying low-yielding assets on our balance sheet following rapid increases in interest rates over the past few years. These assets have been earning interest below current market rates, which has impacted our earnings and ability to reinvest and expand our business. We had the opportunity to raise approximately $70 million in capital to support the sale of these low-yielding assets and reinvestment of the proceeds into assets with higher rates."

13:08 EST Texas Instruments awarded up to $1.6B in CHIPS Act funding - Texas Instruments and the U.S. Department of Commerce announced an award agreement of up to $1.6B in direct funding through the U.S. CHIPS and Science Act, following the preliminary memorandum of terms announced in August 2024. The funding will help support three of TI's new 300mm wafer fabs currently under construction in Texas and Utah. Support from the CHIPS Act, including the 25% investment tax credit, will help TI provide a geopolitically dependable supply of essential analog and embedded processing semiconductors. "As the largest analog and embedded processing semiconductor manufacturer in the U.S., TI is uniquely positioned to provide dependable, low-cost 300mm semiconductor manufacturing capacity at scale," said Haviv Ilan, president and CEO of Texas Instruments. The CHIPS Act direct funding will support TI's investments through 2029 for three large-scale 300mm wafer fabs in Sherman, Texas, and Lehi, Utah. Specifically, the CHIPS Act direct funding will be distributed upon completion of project milestones, supporting: Cleanroom construction and tool installations at SM1 in Sherman, Texas; Shell construction of SM2, a second fab in Sherman, Texas; and Cleanroom construction and tool installations at LFAB2, a second fab in Lehi, Utah. Combined, TI's three new fabs in Texas and Utah will create 2,000 company jobs, along with thousands of indirect jobs for construction, suppliers and supporting industries. TI is also investing in building its future workforce. As part of the CHIPS Act award agreement, TI will also receive up to $10M for workplace development efforts in Texas and Utah.

13:01 EST Baker Hughes reports U.S. rig count unchanged at 589 rigs

12:17 EST ZenaTech Inc trading resumes

12:11 EST Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application - Shares of Ironwood Pharmaceuticals (IRWD) are up $1.17, or 30%, to $5.06 after Zealand Pharma (ZLDPF) announced that the Food and Drug Administration has issued a Complete Response Letter for the company's New Drug Application for glepaglutide, a long-acting GLP-2 analog, under development for the treatment of adult patients with short bowel syndrome with intestinal failure who are dependent on parenteral support. "While we are certainly disappointed in the FDA's decision, we remain confident that the data showed robust and compelling evidence of both efficacy and safety for glepaglutide treatment. We remain firm in our belief that glepaglutide provides a significant advance in GLP-2-based therapies for the potential treatment of SBS patients who are dependent on parenteral support," said David Kendall, MD, Chief Medical Officer of Zealand Pharma. In November, along with Ironwood's earnings report, CEO Tom McCourt had stated: "With apraglutide, we continue making progress in preparing the NDA submission and remain on track to complete the submission in the first quarter of 2025. Our team is focused on getting apraglutide to market as soon as possible, and we look forward to providing more updates on our progress in the months ahead. We believe that, if approved, apraglutide would be the drug of choice among physicians to treat adult patients with short bowel syndrome who are dependent on parenteral support."

12:04 EST Netflix announces new documentary series on Mike Tyson - Netflix announced that its newest sports series will look at the life of boxer Mike Tyson. "Known as the youngest heavyweight champion in history, Tyson's legacy extends far beyond the ropes of the boxing ring, cementing him as one of the most compelling and polarizing figures of our time. From his meteoric rise as the "Baddest Man on the Planet" to his personal struggles - including a period of incarceration and widely publicized struggles - and eventual redemption, this series will explore the man behind the gloves," Netflix stated. Reference Link

12:00 EST Clearwater Paper rises 21.8% - Clearwater Paper is up 21.8%, or $5.38 to $30.09.

12:00 EST Debt Resolve falls -8.5% - Debt Resolve is down -8.5%, or -$2.73 to $29.47.

12:00 EST Innovative Industrial Properties falls -22.3% - Innovative Industrial Properties is down -22.3%, or -$21.24 to $74.10.

10:41 EST Netflix secures U.S. rights to FIFA Women's World Cup for 2027, 2031 - In a post to the company's "Tudum" news site, Netflix stated: "Netflix has secured the exclusive US rights to the FIFA Women's World Cup for 2027 and 2031, marking the first time the tournament will appear on a streaming service. The 2027 tourney, which runs from June 24 to July 25, will feature 32 teams from across the globe, competing in 12 cities throughout Brazil, the host country. The 2031 location will be announced at a later date. But the matches are just the start of it. Studio shows and top-tier talent will supplement coverage with commentary and entertainment. And in the lead-up to the tournament, Netflix will produce exclusive documentary programming spotlighting the top players, their journeys, and the explosion of the sport around the globe." Reference Link

10:12 EST Interlink Electronics Inc trading resumes

10:06 EST Marshall & Ilsley Corporation trading resumes

10:00 EST Novo Nordisk falls -19.9% - Novo Nordisk is down -19.9%, or -$20.60 to $82.84.

10:00 EST Innovative Industrial Properties falls -22.8% - Innovative Industrial Properties is down -22.8%, or -$21.75 to $73.59.

10:00 EST Clearwater Paper rises 17.0% - Clearwater Paper is up 17.0%, or $4.20 to $28.91.

09:56 EST CFPB sues JPMorgan, Bank of America and Wells over Zelle - The Consumer Financial Protection Bureau sued the operator of Zelle and three large banks "for failing to protect consumers from widespread fraud on America's most widely available peer-to-peer payment network." The agency said, "Early Warning Services, which operates Zelle, along with three of its owner banks - Bank of America (BAC), JPMorgan Chase (JPM), and Wells Fargo (WFC) - rushed the network to market to compete against growing payment apps such as Venmo and CashApp, without implementing effective consumer safeguards." The CFPB says customers of the three banks have lost more than $870M over the network's "seven-year existence due to these failures." Reference Link

09:49 EST BlackBerry rises 9.4% - BlackBerry is up 9.4%, or 28c to $3.26.

09:48 EST Cango falls -9.9% - Cango is down -9.9%, or -57c to $5.19.

09:47 EST PainReform Ltd trading resumes

09:46 EST JBT Corp. reports expiration of voluntary takeover offer for Marel hf - JBT Corporation (JBT) earlier announced that JBT's voluntary takeover offer to acquire all issued and outstanding shares of Marel hf. (MRRLF) expired on December 20, 2024, at 12:00 PM GMT. JBT said it has now satisfied all conditions to the offer, including the minimum acceptance condition with at least 90% of all issued and outstanding shares of Marel having been validly tendered in the offer. Further information regarding the final result of the offer, including the number of shares tendered, will be disclosed in JBT's upcoming 8-K filing. JBT will complete the offer in accordance with its terms given the minimum acceptance conditions and other required conditions have been met. "Today marks the final major milestone in combining JBT and Marel to form a leading food and beverage process company," said Brian Deck, President and CEO of JBT. "We are pleased with the outcome of the Marel shareholders' tender decisions and extend our appreciation to shareholders for supporting the transaction. The compelling industrial logic of this transaction is clear, and we are focused on delivering meaningful value for the combined company's customers, employees, and shareholders." The settlement of the transaction is expected to occur on January 2, 2025. All Marel shareholders who validly tendered their shares had the option to elect to receive either all cash, all JBT common stock, or a combination of cash and JBT common stock in respect of their Marel shares, subject to the proration feature. It is JBT's intention to acquire all of the issued and outstanding Marel shares not yet validly tendered and to apply for the Marel shares to be delisted from Nasdaq Iceland hf. and Euronext Amsterdam as soon as permitted and reasonably practicable under applicable laws and regulations. In conjunction with the combination of JBT and Marel, JBT will change its corporate name and stock ticker symbol to "JBT Marel Corporation" and "JBTM," respectively, which is expected to occur on or about January 2, 2025. JBTM shares will remain listed on the NYSE with a secondary listing on Nasdaq Iceland. JBT has secured an approval for secondary listing on Nasdaq Iceland. Shares of JBTM are expected to commence trading on both NYSE and Nasdaq Iceland on January 3, 2025. Goldman Sachs Co LLC is acting as JBT's financial advisor and Kirkland & Ellis LLP and LEX are serving as JBT's legal counsel. Arion banki hf. is acting as JBT's lead manager for the Icelandic offer and advising on the Icelandic listing, and ABN AMRO Bank N.V. is acting as JBT's Euronext Amsterdam Exchange agent.

09:40 EST Invizyne Technologies Inc trading resumes

09:37 EST PainReform Ltd trading halted, volatility trading pause

09:30 EST Invizyne Technologies Inc trading halted, volatility trading pause

09:25 EST Deutsche Bank unit to pay $4M for untimely filing certain SARs - The SEC charged registered broker-dealer Deutsche Bank Securities Inc., a subsidiary of Deutsche Bank AG, for failing to file certain Suspicious Activity Reports, or SARs, in a timely manner. Deutsche Bank Securities has agreed to pay a $4M civil penalty to settle the SEC's charges. According to the SEC's order, Deutsche Bank Securities received requests in connection with law enforcement or regulatory investigations or litigation that prompted it to conduct SARs investigations. However, the SEC's order finds that, in certain instances from April 2019 to March 2024, Deutsche Bank Securities failed to conduct or complete the investigations within a reasonable period of time, including at least two instances where Deutsche Bank Securities took more than two years to file the SARs. The SEC's order finds that Deutsche Bank Securities violated Section 17(a) of the Securities Exchange Act and Rule 17a-8 thereunder. Without admitting or denying the SEC's findings, Deutsche Bank Securities agreed to a censure, a cease-and-desist order, and the civil penalty. Reference Link

09:23 EST San Juan Basin Royalty Trust says no cash distribution for December - Argent Trust Company, as the trustee of the San Juan Basin Royalty Trust, reported that it will not declare a monthly cash distribution to the holders of its Units of beneficial interest due to excess production costs for the Trust's subject interests during the production month of October 2024, as well as continued low natural gas pricing. Excess production costs occur when production costs and capital expenditures exceed the gross proceeds for a certain period. Excess production costs for this reporting period are due primarily to significant lease operating expenses and capital expenditures associated with Hilcorp San Juan L.P.'s 2024 capital project plan.

09:21 EST Wells Fargo, LPL Financial charged for submitting deficient trading data to SEC - The SEC announced settled charges against Wells Fargo Clearing Services LLC (WFC) and LPL Financial LLC (LPLA) for failing to provide complete and accurate securities trading information, known as blue sheet data, to the SEC. Wells Fargo and LPL each agreed to pay a $900,000 civil penalty to resolve the SEC's charges. According to the SEC's orders, over a period of several years, Wells Fargo and LPL each made numerous blue sheet submissions to the SEC that contained inaccurate or missing information about securities transactions and the firms or customers involved in the transactions, as well as other deficiencies. The SEC's order against Wells Fargo finds that, as a result of approximately 15 types of errors, Wells Fargo made approximately 11,195 blue sheet submissions to the SEC that contained missing or inaccurate data for at least 10.6 million total transactions. The SEC's order against LPL finds that, as a result of 10 types of errors, LPL made at least 3,679 blue sheet submissions that contained misreported or missing data for at least 399,000 total transactions. Separately, the Financial Industry Regulatory Authority (FINRA) reached settlements with Wells Fargo and LPL for related conduct. Reference Link

09:19 EST Carnival sees FY25 newbuild capital expenditures $1.1B - For full year 2025, newbuild capital expenditures are $1.1B and non-newbuild capital expenditures are $2.5B. These future capital expenditures will fluctuate with foreign currency movements relative to the U.S. Dollar. In addition, these figures do not include potential stage payments for ship orders that the company may place in the future.

09:17 EST E2open promotes Pawan Joshi to CSO, names Rachit Lohani CPTO - E2open announced the promotion of Pawan Joshi to chief strategy officer, or CSO, a new executive role responsible for driving corporate strategy and growth through strategic client engagement and break-through innovation. E2open also welcomes Rachit Lohani as chief product and technology officer, or CPTO, a new executive role bringing together product management, engineering, and technology.

09:11 EST Channel Therapeutics highlights difference between NaV1.7, NaV1.8 - Channel Therapeutics (CHRO) is providing a statement regarding Vertex Pharmaceutical's (VRTX) recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. Characteristics of Selective NaV1.7 Inhibition: NaV1.7 is a well-studied drug target with strong genetic validation - studies of inheritable pain disorders demonstrate that the spectrum of NaV1.7 activity validates the importance of this target. Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing pain.

09:09 EST HWH International, Sharing Services furthers collaboration in robotics field - HWH International and its partner Sharing Services Global Corporation are taking further steps in their collaboration in the robotics field. Among these, HWH is proud to highlight its U.S. based partner SHRG's membership in the Association for Advancing Automation and attendance at the A3 Business Forum in Orlando Florida in January 2025. As HWH's U.S. partner, SHRG commences its launch in the first quarter of 2025 to distribute robotics throughout the U.S. in several different sectors, membership in this organization is important for access to the top speakers, contacts and experts in the industry. HWH and SHRG share an optimism that the integration of robots into diverse areas of everyday life will offer growth opportunities to businesses that engage with the industry to find new collaborations.

09:06 EST Triller unveils new vision, business updates during Investor Day - Triller Group at a webinar showcased the Company's strategic direction and updates and insights from its leadership team. Wing Fai Ng, the Company's CEO, and Mark Carbeck, Triller Corp.'s CFO, unveiled the rationale behind the recent merger. Sean Kim, CEO of Triller App and Triller Platform, articulated the platform's mission to become the world's most creator-focused social media platform offering discovery, monetization, and ownership. Kosta Jordanov, CEO and Founder of TrillerTV, shared the platform's vision for live sports streaming. Chief Strategy Officer Jeroen Nieuwkoop highlighted the Group's strategic direction, emphasizing the high-growth potential of its assets.

09:04 EST Renovaro BioSciences enters into strategic collaboration with Nebul - Renovaro (RENB) announced its subsidiary Renovaro Cube has entered into a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. As part of this initiative, Renovaro Cube plans to deploy a dedicated NVIDIA (NVDA) SuperPOD powered by NVIDIA DGX B200 systems, which feature the latest Blackwell GPU's, and apply NVIDIA Parabricks functionality to ensure optimal performance on the NVIDIA clusters. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance, providing the computational power necessary to integrate AI across medium-sized hospitals.

09:03 EST Battalion Oil terminates merger agreement with Fury Resources - Battalion Oil has terminated the previously disclosed Agreement and Plan of Merger with Fury Resources. As of this morning, Fury was not able meet the obligations and close the transaction contemplated by the Merger Agreement. Over the past year, in order to facilitate the transaction, the Company and Fury entered into numerous amendments to the terms of the Merger Agreement. In support of the transaction, the holders of all of the outstanding shares of the preferred equity of the Company, Luminus Management, Gen IV Investment Opportunities, and funds and accounts managed by Oaktree Capital Management, or their respective affiliates, had agreed to contribute to Buyer 100% of their preferred equity of the Company in exchange for new preferred shares of Buyer. Despite these commitments and amendments, Fury was unable to provide evidence of additional equity financing or to timely close the transaction as required by the Merger Agreement. In connection with the termination of the Merger Agreement, the Company has cancelled the special meeting of stockholders, scheduled for December 27, 2024.

08:49 EST Eos Energy announces factory 2 location search outside Mon Valley Works - Eos Energy Enterprises announced its search for a new manufacturing facility in addition to the Mon Valley Works expansion under Project AMAZE. This expansion is part of the Company's broader strategy to scale up its operations to meet the rapidly growing demand for renewable energy solutions and to further its commitment to American manufacturing and energy independence.

08:43 EST TruGolf enters letter of intent to create collaboration with D3 Sports - TruGolf announces it has entered into a letter of intent to create a strategic collaboration with D3 Sports Tech. This collaboration will focus on innovations to enhance gameplay with more realistic and exciting experiences. The collaboration partnership will also elevate TruGolf's advanced game and player data analytics to provide insights that increase engagement to ultimately provide more exciting virtual experiences that surpass what can be done out on the course.

08:42 EST Enovix announces first EX-2M samples to mobile phone customers - Enovix announced the major milestone of shipping second-generation EX-2M samples to customers manufactured in its Malaysian Fab 2 plant. Consistent with its plan, the samples demonstrated an energy density improvement of approximately 10% over EX-1M products scheduled for mass 2025 production in Malaysia. EX-2M is expected to launch in 2026 and assure Enovix's energy density lead in the smartphone industry. As a result of recent manufacturing progress, the Company also announced that it had received its first mobile phone customer purchase order this week. The order for custom samples from a customer with an NDA was predicated on a major joint-development agreement milestone achievement. The product is expected to ramp into mass production in late 2025.

08:40 EST Horizon Space Acquisition I announces revised contribution to trust account - Horizon Space Acquisition I announced that, in connection with its previously announced extraordinary general meeting of shareholders in lieu of an annual general meeting to be held on December 20, 2024, the Company has revised the terms and conditions in connection with the proposal to amend the Company's current charter and the proposal to amend the trust agreement with the trustee of the Company's trust account. The revised terms and conditions, among other things, include: If the shareholders approve the MAA Amendment Proposal and the Trust Amendment Proposal, the Company will have until December 27, 2024 to complete a business combination and may elect to extend up to twelve times, each by a one-month extension, for a total up to twelve months to December 27, 2025. For each New Monthly Extension, the required contribution to the trust account of the Company is revised to the amount of $120,000 for all remaining public shares. The Investment Management Trust Agreement dated December 21, 2022, between the Company and Continental Stock Transfer & Trust Company will be amended, among the others, that to effectuate each New Monthly Extension, a deposit of $120,000 for all remaining public shall be made to the Trust Account. In addition to the above, the Company agrees to file a current report on Form 8-K in connection with each New Monthly Extension pursuant to applicable rules and regulations. In the event that any New Extension Fee is not deposited into the Trust Account by 27th of each succeeding month after the Meeting until November 27, 2025, the Company has agreed to grant irrevocable rights to the trustee to force the Company to liquidate the Trust Account within two weeks from 27th of such month, pursuant to terms and conditions of the Trust Agreement. Furthermore, as disclosed in the Company's registration statement on Form S-1 in connection with its initial public offering, when redeeming public shares, the proceeds then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay franchise and income taxes as well as expenses relating to the administration of the Trust Account will be used to fund the redemption. The Company agrees not to use such trust proceeds including interests earned to pay dissolution expenses.

08:38 EST YY Group's YY Smart Tech expands strategic partnership network - YY Group announces that its subsidiary and technology arm, YY Smart Tech, YYST, is strengthening its partnership network with leading solution providers and system integrators to deliver cutting-edge services to customers across Singapore and the broader Asia region. This strategic partnership will elevate YY Smart Tech's service offerings by delivering innovative solutions in Cybersecurity, IT Infrastructure, and Operational Technology to clients across diverse sectors, including Government, Banking, and Enterprise. The partnership, valued at USD $5 million, will span three years starting in 2025. Key partners include Infinity Cybersecurity, which will drive secure and optimized technological solutions to meet evolving customer needs.

08:36 EST Brand Engagement Network , Cataneo leverage AI with radio industry leaders - Brand Engagement Network and Cataneo announced a collaborative pilot program with Vybroo and Grupo Siete aimed at modernizing Mexico's radio advertising landscape. By combining BEN's trusted AI technology with Cataneo's MYDAS platform, radio stations could benefit from streamlined advertising workflows, driving engagement, and enhancing the overall listener experience across Mexico's radio market. "Radio continues to be one of Mexico's most impactful media platforms. Through this collaboration, we are deploying AI-driven tools to deliver more effective solutions for advertisers while enriching the listener experience," said Paul Chang, CEO of BEN.

08:36 EST InterCure secures funding to support recovery of Nir Oz facility - InterCure is pleased to announce that further to the company's prior reports regarding the war-related damages and the reconstruction efforts of its facility in Kibbutz Nir Oz, the company was successful in obtaining funding commitments of approximately $18.2M, which may increase to approximately $29.8M. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. Funding also includes a loan from a major Israeli bank. Completing the post-war damage recovery processes will enable the company to return to profitable growth without further delay, including exercising the cookies agreement and expanding international operations in Germany, the UK, and Australia. The company anticipates receiving additional substantial payments from the Israeli authorities, as part of the full compensation for war related damages, including loss of profits the Company is entitled to.

08:35 EST HCA Healthcare chief ethics, compliance officer Kathi Whalen to retire - HCA Healthcare announced that Wendy Warren, a more than 10-year veteran of HCA Healthcare, has been appointed senior vice president and chief ethics and compliance officer, effective March 3, 2025. Warren succeeds Kathi Whalen, who is retiring after 27 years with the company. Warren will lead the company's ethics, compliance and regulatory department.

08:32 EST Mission Produce sees FY25 capital expenditures $50M-$55M - Industry volumes in the FY25 first quarter are expected to be consistent with the prior year period. Barnard continued, "Looking ahead to fiscal 2025, we will continue to focus on operational excellence, strategic growth initiatives, and sound capital allocation to drive shareholder value. While we anticipate some pricing moderation as additional supply sources become available, this environment typically supports increased consumption, and we remain well-positioned to capitalize on this growth through our unique capability to provide consistent year-round avocado supply. Beyond avocados, we are also excited about growing our mango program and expanding our presence in blueberries this year, both of which leverage our existing assets and capabilities while providing additional long-term growth opportunities."

08:26 EST Talen Energy announces completion of refinancing transactions - Talen Energy announced that the Company has closed on several financing transactions that improve the Company's debt structure and financing cost. The Transactions include: repricing the Company's existing $700M revolving credit facility to reduce the current interest rate margin by 100 basis points, extending the maturity of the Revolver from May 2028 to December 2029, and increasing available letter of credit capacity under the Revolver from $475M to $700M; repricing its existing $859M in Term B loans to reduce the current interest rate margin by 100 basis points to align pricing with its recently issued $850M in incremental Term B loans; issuing a new, standalone $900M secured LC facility; repaying in full its existing $470M in Term C loans and terminating the associated LC facility; and terminating its existing $75M standalone bilateral LC facility. Together, the Transactions are expected to result in annual savings of approximately $28M in interest, fees, and other expenses, not including additional interest from the Incremental TLB. In conjunction with the Transactions, Talen obtained certain amendments increasing its flexibility for restricted payments, investments, and dispositions under its primary credit agreement, which governs the Revolver, Existing TLB, Incremental TLB, and New LC Facility.

08:15 EST Sealsq integrates post-quantum cryptographic chips on WISeSat satellites - SEALSQ announced the integration of its latest post-quantum cryptographic chips on WISeSat satellites. This milestone development underscores SEALSQ's commitment to securing satellite communications in an era of emerging quantum computing threats. See demo here. This partnership leverages SEALSQ's cutting-edge semiconductor expertise and WISeSat's innovative satellite IoT connectivity solutions. With the rise of quantum computing, traditional encryption methods are at risk of being compromised. By converting data into light particles and transmitting it through a constellation of satellites, WISeSat and SEALSQ are pioneering a potential solution to mitigate these future vulnerabilities.

08:14 EST Guardant Health enters partnership with MiBA - Guardant Health and Meaningful Insights Biotech Analytics, or MiBA announced a partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network.

08:11 EST Aqua Metals announces operational milestones at pilot facility - Aqua Metals announced operational milestones achieved at its pilot facility, demonstrating the effectiveness and scalability of its proprietary Li AquaRefining process. The company also announced the closing of a $1.5M bridge loan to fund operations, while the Company continues to pursue ongoing due diligence and strategic initiatives for long-term financing. Aqua Metals recently completed the first multi-week continuous operation campaign at its pilot facility outside Reno, demonstrating its ability to deliver exceptional recovery rates and produce battery-grade critical minerals. Key accomplishments include: High Recovery Rates: Achieved over 99% recovery rates for lithium, cobalt, and nickel from black mass using Aqua Metals' proprietary leaching process and 100% recycled solvent, lowering recycling costs and eliminating waste. Battery-Grade Lithium Carbonate: Produced over 600 lbs. of battery-grade lithium carbonate to date in December. Nickel and Cobalt Production: Recovering nickel at 96.5%+ purity and cobalt at 99%+ purity levels. The Company has designed the Sierra ARC to achieve consistent battery-grade metals production. Enhanced Process Controls: Demonstrated advanced controls that improved throughput and efficiency, setting the stage for scalability at the commercial level. Continuous Operations: Successfully operated the pilot facility around the clock for three weeks, achieving over 90% uptime.

08:10 EST reAlpha announces the launch of its enterprise version for relocation programs - reAlpha Tech launched the enterprise version of its commission-free AI homebuying platform. reAlpha Enterprise will specifically cater to corporate relocation programs. This strategic initiative targets the $25 billion employee relocation market by offering cost savings for both employers and employees. "reAlpha Enterprise addresses a critical market need by eliminating buy-side real estate commission expenses and bringing the entire process into one place," said Giri Devanur, CEO of reAlpha. "By leveraging our commission-free real estate platform, we aim to provide partnered companies and their employees with a seamless solution to homebuying, which many Americans identify as the most stressful life event."

08:09 EST Sernova reschedules Annual General, Special Meeting of Shareholders - Sernova will hold its annual general and special meeting of shareholders on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to be held on January 7, 2025, at 1:00pm ET, was postponed so that Sernova and its agents are able to complete the mailing of its meeting materials through Canada Post to meet regulatory requirements. The record date of November 12, 2024, has not changed.

08:08 EST Stantec appoints Christopher Lopez, Rick Eng to board - Stantec announced the appointments of Christopher Lopez and Richard Eng to the company's Board of Directors, effective January 1, 2025. Lopez has served in various senior leadership positions including, most recently, as Chief Financial and Regulatory Officer at Hydro One Limited. Eng spent over 17 years at Brookfield Asset Management, where he served as a Managing Partner in the Infrastructure Group.

08:08 EST Galectin Therapeutics announces results from NAVIGATE trial on belapectin - Galectin Therapeutics announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal hypertension. The primary endpoint was defined as the prevention of varices, assessed as a composite clinical outcome that included subjects with any varices, those with intercurrent events, or those without an endoscopy or intercurrent events at 18 months. Intercurrent events were defined as any liver-related complication, treatment discontinuation due to adverse events, use of non-selective beta-blockers or GLP-1 agonists for more than 12 months or undergoing a TIPS procedure. The most common intercurrent event was prolonged use of NSBB or GLP-1 agonists. In the intent-to-treat population, while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach statistical significance. The per-protocol population was pre-defined as subjects who completed 18 months of therapy with upper endoscopy performed at both baseline and 18 months. In the PPP, the incidence of varices was reduced by 48.9% in the belapectin 2 mg/kg dose group

08:07 EST Aridis Pharmaceuticals continuing to explore 'multiple paths to monetize' assets - Aridis Pharmaceuticals announced a corporate update on recent developments. The company said, "The Company continues to diligently explore multiple paths to monetize its assets amidst a protracted challenging capital market and limited internal resources. During the second half of this year it has been in discussions with other pharmaceutical companies and investment firms on possible partnerships and investments in the clinical product candidates AR-301, AR-320, AR-501, and the APEX platform technology. The Company has substantially reduced its operational cash burn by delaying the expenses associated with SEC filings in favor of business development discussions with potential partners and investors. As a result of voluntary non-compliance, the Company was transitioned to and expects to continue to be listed on the OTC Expert Market until a positive outcome from the business development effort on one or more of its programs. Importantly, two promising developments have been achieved involving the lead assets AR-301 and AR-501 that, if realized, are expected to generate near term revenues and shareholder value: The Company recently executed an Asset Acquisition Terms Agreement with an undisclosed pharmaceutical company to assign exclusive ownership of AR-501 upon receiving the Partner's payments totaling $6,500,000. Two payments of $3,250,000 each are expected to be received in the first and second quarter of 2025, respectively. The Partner is further obligated to make annual royalty payments to Aridis of 12% to 15% of the net sales revenue for up to 10 years following the first commercial sale. Development status: AR-501 is being developed as a therapeutic treatment for chronic bacterial lung infections in cystic fibrosis patients. A Phase 1 trial in healthy adults and a Phase 2a trial in cystic fibrosis patients have been completed. The primary endpoint of safety was achieved in both studies, showing that AR-501 was well tolerated when administered as an inhaled dosage form over several weekly treatments. The pharmacokinetic data showed effective delivery of AR-501 into the lungs of CF patients and a fast clearance rate. The positive clinical trial data also facilitated the filing for non-dilutive grant funding support from governmental sources and non-governmental organizations , which we intend to explore. The discussions with potential partners and investors to continue the development of AR-301 resulted in an investment proposal from a globally recognized private investment firm in an amount that the Company believes is sufficient to complete the second and final Phase 3 study and product approval. The Company is working closely with the investment firm to satisfy specific requirements for the closing of investment. Details of the investment proposal and the progress toward investment closing are expected to be disclosed in 1Q25. Development status: AR-301 is being evaluated for the adjunctive therapeutic treatment of Ventilator Associated Pneumonia. The first of two planned Phase 3 clinical trials saw significant reduction in patient enrollment that was brought about by the COVID-19 pandemic, resulting in an under-powered study. However, despite a small sample size, a positive efficacy trend in favor of AR-301 in VAP patients was observed. Remarkably, in a prespecified subpopulation of adults 65 years and older, the efficacy signal was increased by approximately 300%, reaching statistical significance level. Furthermore, AR-301 treated patients had a median reduction of length of stay in the intensive care unit and hospital by 7 days and by 9 days in the over 65 subpopulation. The clinical data and the proposed design for the second and final Phase 3 study were presented to the FDA and the European Medicines Agency. Concurrence has been achieved with the regulators on a single, globally harmonized Phase 3 study for licensure. Moving the final Phase 3 study forward is predicated on finalizing the above proposed investment. Following a lengthy effort to resolve the product licensing dispute with MedImmune, a mutually satisfactory resolution has not been reached. The Company is currently exploring its legal options for loss recovery. Development status: AR-320 is being developed for the prevention of Ventilator Associated Pneumonia in a pivotal Phase 3 clinical trial. The AR-320-003 Phase 3 clinical study was initiated in 2022, with 24 patients enrolled. The study was placed on voluntary hold at the time that the product license dispute with MedImmune arose, and is now expected to be discontinued. The Company's primary focus in the past year has been on business development discussions related to its clinical product candidates, on laboratory activities to support two NIH active grant awards and on one funded external collaboration related to the APEX platform technology. Operating expenses, including clinical trial and clinical supplies manufacturing have been substantially lowered while all clinical trials have either been completed or terminated. The Company has been working with its lead lender Streeterville Capital to service the loan. The Company's near-term goals will be to successfully complete the business objectives described above and to become current on its SEC filings in the first half of 2025."

08:05 EST BAE Systems awarded $68M in U.S. Army contracts - BAE Systems has been awarded $68M in contracts to produce an additional 44 Cold Weather All-Terrain Vehicles for the U.S. Army. The order includes a $48M add-on to the existing full-rate production contract, awarded in August 2022, and a $20M award for 2025 funding.

08:04 EST Apollomics announces results from Phase 3 bridging trial of uproleselan - Apollomics announced the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The median overall survival in the uproleselan arm was 9.3 months versus 14.3 months in the chemotherapy-only arm. Addition of uproleselan to chemotherapy was generally well tolerated, with a similar safety profile to the control arm. The incidence of serious adverse events was 43% in the uproleselan arm versus 39% in the chemotherapy-only arm. The most common serious adverse events in the uproleselan arm were decreased platelet count, infectious pneumonia, and sepsis.

08:03 EST Radiopharm Theranostics receives approval to start Phase 1 trial of RAD 202 - Radiopharm Theranostics has been granted Belberry Human Research Ethics Committee approval in Australia to initiate its First-In-Human Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors. The open-label Phase 1 trial, entitled 'HEAT', is a dose escalation trial of 177Lu-RAD202, and is designed to evaluate the safety and preliminary clinical activity of this novel radiotherapeutic in individuals with HER2-expressing advanced cancers. RAD 202 is a single-domain monoclonal antibody that targets the Human Epidermal growth factor Receptor 2, which is overexpressed in breast cancer as well as several other solid tumors, and represents a validated target in oncology. The multicenter study is planned to recruit across Australia, with the support of leading oncology care provider GenesisCare CRO. Previous data1 demonstrated the safety and biodistribution of 99mTc-labeled RAD 202 in humans. Additional preclinical findings examining the therapeutic effect in HER2-positive xenografts were also recently reported with 177Lu-labeled RAD 2022. These data demonstrated tumor growth inhibition, significantly prolonged survival time, and further justify FIH dose finding studies.

08:02 EST Woodward signs agreement to acquire Safran's Electronics & Defense business - Woodward announced that it has signed a definitive agreement to acquire the Safran Electronics & Defense electromechanical actuation business based in the United States, Mexico and Canada. The acquisition includes intellectual property, operations assets, talent, and long-term customer agreements for Horizontal Stabilizer Trim Actuation systems for aircraft stabilization to support safe and efficient flight, notably used for the Airbus A350.

07:54 EST Lowell Farms appoints Philippe Faraut as CFO - Lowell Farms announces the appointment of Philippe Faraut as CFO of the Company, effective immediately. Most recently, he served as CFO of iAnthus. Faraut steps into the CFO role, succeeding CEO Mark Ainsworth, who had been serving as Interim CFO.

07:50 EST Knife River to acquire Strata for $454M - Knife River announced that it has entered into a definitive agreement to acquire Strata. Based on Strata's projected 2025 adjusted EBITDA, the purchase price of $454M reflects a multiple in the high single digits. The transaction is expected to close in the first half of 2025, subject to regulatory approval and customary closing conditions. Knife River expects to use cash on hand and the proceeds from the issuance of long-term debt to finance the acquisition.

07:36 EST Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada - PMGC Holdings, formerly known as Elevai Labs, plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs to PMGC Holdings and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market under the ticker symbol "ELAB." The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024. The company said, "The Company's name change reflects its expanded vision and commitment to building a portfolio of operating companies and assets with significant growth potential. As PMGC Holdings, the Company will concentrate on enhancing operational efficiencies across its existing entities, pursuing synergistic acquisitions, and considering strategic divestitures of assets or companies that are underperforming or do not align with its long-term strategy. In doing so, the Company aims to reduce costs, optimize returns, and enhance shareholder value."

07:34 EST Quantum diversifies treasure with 1M purchase of bitcoin - Quantum BioPharma announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoi and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency. This move reflects the company's belief in the potential of Bitcoin and other currencies to provide a return on investment for shareholders. The company is now set up to receive financing in cryptocurrencies as well as executing other types of transactions in cryptocurrencies.

07:31 EST Ballard Power announces orders from two bus manufacturers - Ballard Power Systems announced orders from two bus manufacturers to supply over 90 fuel cell engines, representing approximately 6.4 megawatts of total rated power, for the European and UK city bus market.

07:13 EST Canacol Energy provides drilling update - Canacol Energy provided the following update concerning its ongoing exploration and development drilling programs. The Pibe-1 exploration well was spud on November 23, 2024, and reached a total depth of 11,000 feet measured depth. The well is located approximately 4 kilometers to the north of the recent Chontaduro-1 discovery. The well encountered 1,044 feet true vertical depth of gross gas column within the Cienaga de Oro sandstone reservoir. The CDO was perforated across one zone located between and 7,424 ft and 7433 ft TVD and was flow tested at 3.8 million standard cubic feet per day for 3.7 hours with an average tubing head pressure of 2701 psi, and subsequently 5.1 MMscfpd for 41.5 hours with an average THP of 2628 psi. The well was placed on permanent production on December 13, 2024, and is currently flowing at a rate of 5.5 MMscfpd. The Natilla-2 exploration well was spud on November 2, 2024, and is targeting a large natural gas prospect with primary and secondary targets within the CDO and overlying Middle Porquero Formations respectively. The well has reached a depth of 13,631 ft MD within the mid Porquero Formation, where drilling difficulties were encountered. The current operation is tripping out of the hole to change the configuration of the bottom hole assembly and then resume drilling to the main targets within the next week. The Corporation has spud the Pibe-2 appraisal well located on the VIM-21 Exploration and Exploitation Contract from the existing Pibe-1 drilling platform. The Corporation anticipates results within the next 3 weeks. The Corporation anticipates spudding the Clarinete-11 development well located on the VIM-5 Exploration and Production Contract within the next 2 days. The well is targeting gas bearing sandstones of the CDO reservoir with results expected prior to year end.

07:10 EST XCHG 'not aware of any material news' to account for unusual trading activity - XCHG acknowledges the recent unusual trading activity of its American Depositary Shares. The company said, "The company is not aware of any material news or events that would account for this activity. XCharge is committed to sound corporate governance and transparent communication with its shareholders. The company's operations continue as normal, and its financial condition remains strong. XCharge's business focuses on EV charging solutions, and its ADSs are traded on the Nasdaq Global Market under the unique ticker symbol "XCH." The company encourages investors to rely on factual information and consult with financial advisors when making investment decisions."

07:09 EST Emerita provides results from ongoing metallurgical program for La Romanera - Emerita Resources provides results from its ongoing metallurgical testing program for La Romanera deposit for base and precious metals on its wholly-owned Iberian Belt West Project, IBW. La Romanera and El Cura deposits are unique in the Iberian pyrite belt in that they have significantly elevated gold values and it has been a key objective of the Emerita technical team to develop a process that will maximize the gold recoveries. A two-stage process has now been identified that provides excellent recoveries.

07:08 EST CCC Intelligent Solutions announces $300M share repurchase program - CCC Intelligent Solutions announced that its board of directors has approved a new share repurchase authorization to repurchase up to $300M of the company's outstanding common stock.

07:08 EST Silvaco, Micron Global announce strategic sales partnership - Silvaco Group announced a strategic sales partnership with Micon Global. The partnership between Silvaco and Micon Global is expected to drive Silvaco's expansion across the EMEA market, leveraging Micon Global's expertise to enhance client access to Silvaco's design solutions. "We are excited to partner with Micon Global to bring Silvaco's TCAD, EDA, and SIP solutions to a broader customer base, as we expand our reach across the EMEA market," said Ian Chen, Chief Revenue Officer at Silvaco Group. "We believe Micon Global's deep expertise in the region and strong client relationships will be instrumental in increasing access to our cutting-edge semiconductor design and digital twin modeling solutions, empowering innovation and enabling success for our customers."

07:07 EST Hyzon Motors issues WARN Act notice to employees at certain facilities - Hyzon announced the company has issued a Worker Adjustment and Retraining Notification Act notice to its employees at the company's Bolingbrook, Illinois and Troy, Michigan facilities, as well as to substantially all of its remaining employees in the states of Illinois and Michigan. Hyzon cited its inability to raise funding and the future uncertainty relating to the availability of government subsidies, most notably the California Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project, which the company believes has caused certain of its customers to slow down or suspend their purchasing decisions. If the company cannot raise funds or find a buyer, it is expected that the reduction in force will be completed in February 2025. The Notice begins the 60-day notice period that must be given prior to idling operations and laying off employees under the WARN Act.

07:06 EST Alpha Star Acquisition receives delisting letter from Nasdaq - Alpha Star Acquisition has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Staff has determined that the Company's securities will be delisted from The Nasdaq Stock Market; trading of the Company's Ordinary Shares, Units, Rights, and Warrants will be suspended at the opening of business on December 23, 2024; and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. Pursuant to Nasdaq Listing Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. Since the Company failed to complete its initial business combination by December 13, 2024, the Company did not comply with IM-5101-2, and its securities are now subject to delisting. The Company will not appeal Nasdaq's determination to delist the Company's securities and accordingly, the Company's securities will be suspended from trading on Nasdaq at the opening of business on December 23, 2024. The Company intends to apply for the listing of its securities on the OTC market under the same ticker symbols after they are delisted from Nasdaq. The delisting from Nasdaq does not affect the Company's previously announced business combination with OU XDATA GROUP, a company incorporated in Estonia, as both parties continue to work to effectuate the closing of the business combination. The merged entity will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. On December 16, 2024, the Company filed a definitive proxy statement for an extraordinary general meeting of shareholders to be held on December 27, 2024, to, among other things, approve amendments to the investment management trust agreement between the Company and Wilmington Trust, N.A. providing the Company with the discretion to extend the date on which to commence liquidating the trust account established in connection with the Company's initial public offering up to six additional times, each by a period of one month, from December 15, 2024 to June 15, 2025 by depositing into the Trust Account $35,000 for each one-month extension. The Company believes that it is very likely that it will fully exercise such discretion to extend the business combination period. The Company and OU XDATA GROUP are working diligently to complete the business combination as soon as practicable.

07:04 EST Plymouth Industrial REIT acquires small bay industrial portfolio for $20.1M - Plymouth Industrial REIT has acquired a portfolio of primarily small bay industrial properties in Cincinnati, Ohio for $20.1M, which equates to an anticipated initial NOI yield of 6.8%. The portfolio consists of nine buildings totaling 258,082 square feet that are currently 96.9% leased to 23 tenants with a weighted average lease term of approximately 2.75 years. The Company has a second tranche of this portfolio that is under contract for $17.9M, which equates to an anticipated initial yield of 7.3%, and is expected to close in the first quarter of 2025, contingent on the satisfaction of customary closing conditions, which cannot be assured. This portfolio consists of four buildings in Cincinnati totaling 240,578 square feet that are currently 98.0% leased to nine tenants with a weighted average lease term of approximately 3.75 years.

07:03 EST Applied Therapeutics appoints Johnson as Executive Chairman, CEO steps down - Applied Therapeutics (APLT) announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman; Dr. Shoshana Shendelman has stepped down as Chair and CEO; and Les Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer.

07:02 EST Innovative Industrial Properties reports default by PharmaCann on all leases - Innovative Industrial Properties, through indirect, wholly owned subsidiaries serving as landlords, previously entered into leases with PharmaCann and its affiliates as tenants for eleven properties that IIP owns, which represented 17% of IIP's total rental revenues for the three and nine months ended September 30. On December 19, PharmaCann defaulted on its obligations to pay rent for the month of December under six of the eleven Leases, for properties located in Illinois, Massachusetts, Michigan, New York, Ohio and Pennsylvania. December rent, including base rent, property management fees and estimated tax and insurance payments, totaled $4.2M for these six properties. IIP applied security deposits held by IIP pursuant to these Leases for the payment in full of the defaulted rent, in addition to late penalties and interest. Although PharmaCann paid rent in full under the remaining five Leases totaling $90,000 for the month of December, as a result of cross-default provisions contained in each of the Leases, on December 19, PharmaCann also defaulted on its obligations under these five Leases, as a result of the non-payment of rent on the other six Leases. IIP is continuing discussions with PharmaCann regarding the Leases and expects to enforce its rights under the Leases aggressively, which may include, but is not limited to, commencing eviction proceedings as IIP deems necessary.

06:47 EST Merck closes exclusive global license agreement for LM-299 from LaNova Medicines - Merck announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588M, or approximately 18c per share, in the company's fourth quarter 2024 GAAP and non-GAAP results. LaNova is also eligible to receive up to $2.7B in milestone payments associated with the technology transfer, development, regulatory approval and commercialization of LM-299 across multiple indications, including $300M upon technology transfer anticipated to be completed in 2025.

06:33 EST Cable One amends terms of investment in Mega Broadband Investments - Cable One announced that it has amended the terms of its strategic investment in Mega Broadband Investments Holdings to provide enhanced timing flexibility for Cable One's potential acquisition of full ownership of MBI. Cable One currently owns a 45% stake in MBI, and affiliates of GTCR LLC and MBI management own the balance of MBI. The amendments provide Cable One with enhanced ability to control the timing for acquiring the 55% interest it does not currently own pursuant to the put right held by GTCR, with any such acquisition to occur no earlier than October 1, 2026 unless Cable One elects to close the transaction at an earlier date. As part of the amended partnership agreement, Cable One paid $250M to the other MBI equity holders, and those same other equity holders also received the proceeds from $100m of new MBI debt. The combined $350M of payments will reduce the purchase price payable by Cable One on a dollar-for-dollar basis for the 55% interest in MBI it does not currently own.

06:31 EST Vertiv Holdings acquires certain assets of BiXin Energy Technology, no terms - Vertiv announced the acquisition by its Chinese subsidiary of certain assets and technologies of BiXin Energy Technology Co., a manufacturer of chillers, heat pumps, heat-recovery solutions and air-handling units. Focused on expanding the Vertiv chiller family, the acquisition strengthens Vertiv's portfolio of critical technologies and solutions in support of high-performance compute and AI applications globally. Founded in 2010, BSE brings to Vertiv an established and field-proven presence in the China market and other Asian regions, along with industry patents, advanced technology solutions and strong research and development capabilities that will reinforce Vertiv's global offering.

06:18 EST Fennec announces Pedmarqsi positive recommendation by NICE - Fennec Pharmaceuticals announced that Norgine Pharmaceuticals, a European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence recommending Pedmarqsi for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors. Pedmarqsi is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to less than18 years of age with localized, non-metastatic solid tumors. In March, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize Pedmarqsi in Europe, Australia, and New Zealand.

06:08 EST EShallGo announces $20M investment from CS Fund, enters Tencent ecosystem - Eshallgo (EHGO) and the investment fund CS Asia Opportunities jointly announced an equity investment. According to the securities purchase agreement between the two parties, CS Fund will become one of the shareholders of EHGO by injecting up to $20M in equity investment in tranches. In this cooperation, CS Fund will purchase a total of up to 4,166,660 shares of Eshallgo at a price of $4.80 per share in tranches. This equity cooperation will provide a foundation for Eshallgo's entry into Tencent's (TCEHY) business ecosystem.

06:03 EST Joby Aviation successfully conducts first FAA testing under TIA - Joby Aviation announced it has entered the final phase of certification for its electric air taxi, having conducted its first FAA testing under Type Inspection Authorization. The testing involved pilots from the Federal Aviation Administration evaluating human factors elements of flight safety using an FAA-conforming flight deck in a Joby simulator. The company targets 2025 to start TIA flight testing with first FAA-conforming aircraft, currently being built.

06:01 EST Novo Nordisk shares drop 27% premarket after releasing Cagrisema data

05:58 EST Novo Nordisk to further explore weight loss potential of Cagrisema

05:57 EST Novo Nordisk says patients on Cagrisema lost 22.7% of weight in trial

05:14 EST Humacyte announces FDA approval for Symvess - Humacyte announced that the FDA has granted a full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

05:10 EST Sanofi to acquire rights to develop, commercialize aficamten from Corxel - Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy in Greater China. Aficamten is a cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, Corxel acquired the rights to develop and commercialize aficamten in Greater China from Cytokinetics in accordance with Cytokinetics' global registration programs. Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for aficamten tablets for the treatment of oHCM for Priority Review. Sanofi will now acquire Corxel's rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150M in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and Corxel.

05:04 EST Berkshire acquires additional 8.9M shares of Occidental Petroleum - Berkshire Hathaway (BRK.A, BRK.B) last night disclosed the purchase of an additional 8.9M shares of Occidental Petroleum (OXY) at an average price of $45.99 per share for a total of $409.15M. Berkshire now owns 264.18M shares of Occidental.